November 2, 2021 — Monday was quite an opening day for ObesityWeek 2021. Starting with the lived experience, the meeting then moved quickly into some serious science, clinical care, and policy discussions. But one of the most impressive sessions of the day gave us a “tour de force” of future options under development for obesity care. Our friend Mike […]
October 20, 2021 — Day by day, the prospects for treating obesity are getting better. Late on Monday, detailed results from the longest study yet of tirzepatide came out in Lancet. This was a study using this new drug in people with type 2 diabetes, but the average BMI of these patients was 33. None of them had a […]
September 27, 2021 — It was an exciting possibility. At ObesityWeek 2019, Novartis scientist Laura Coleman presented fascinating results for an experimental drug, bimagumide, in obesity. In a phase 2 study, it yielded impressive improvements in body composition for people with obesity. It wasn’t just making people lose body fat. It helped them also gain muscle mass. Then, it […]
January 26, 2021 — Innovation in obesity care has come a long way. Back in 2010, Sanofi was smarting from the spectacular failure of rimonabant and big pharma was closing down research programs in obesity. But Novo Nordisk forged ahead with an ambitious program and now has a successful portfolio in obesity care to show for it. Nonetheless, we […]
May 7, 2020 — Nonalcoholic steatohepatitis – NASH – is a more severe form of fatty liver disease that can lead to cirrhosis and liver cancer. Like other complications of obesity, people can develop NASH even if their BMI does not fall into the range of obesity. Just like obesity, the prevalence of NASH is growing and the treatment […]
May 4, 2019 — My, how things have changed. Barely more than a decade ago, the dominant drugs for type 2 diabetes caused weight gain. Most big pharma companies were cutting obesity research. Eli Lilly and Sanofi were riding high in diabetes care and turning up their noses at obesity. But now the tables have turned. Sanofi’s diabetes business […]
May 5, 2017 — We confess. Good news about obesity treatment innovation brings a smile here. The options right now are OK, but limited. So new options are especially welcome. This week brought news of progress on two fronts. DNA-PK: A New Drug Target for Mid-Life Obesity NIH researchers this week published their discovery of a critical role for the […]
March 21, 2017 — Gratefully, we can report progress on the next generation of obesity treatment. For starters, John Blundell and colleagues have just published a controlled clinical trial of semaglutide in obesity. The study is a tightly controlled experiment to explain how the drug works. And beyond semaglutide, more options for treating obesity are moving into development. The […]
